JP2002520362A - ジスキネジーの治療 - Google Patents
ジスキネジーの治療Info
- Publication number
- JP2002520362A JP2002520362A JP2000559850A JP2000559850A JP2002520362A JP 2002520362 A JP2002520362 A JP 2002520362A JP 2000559850 A JP2000559850 A JP 2000559850A JP 2000559850 A JP2000559850 A JP 2000559850A JP 2002520362 A JP2002520362 A JP 2002520362A
- Authority
- JP
- Japan
- Prior art keywords
- dyskinesia
- treatment
- use according
- opioid receptor
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000012661 Dyskinesia Diseases 0.000 title claims abstract description 85
- 238000011282 treatment Methods 0.000 title claims abstract description 37
- 150000001875 compounds Chemical class 0.000 claims abstract description 51
- 230000000694 effects Effects 0.000 claims abstract description 50
- 102000051367 mu Opioid Receptors Human genes 0.000 claims abstract description 35
- 108020001612 μ-opioid receptors Proteins 0.000 claims abstract description 35
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 30
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 28
- 230000004913 activation Effects 0.000 claims abstract description 10
- 239000002623 mu opiate receptor antagonist Substances 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims description 28
- 108020004414 DNA Proteins 0.000 claims description 19
- 206010034010 Parkinsonism Diseases 0.000 claims description 19
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 102000053602 DNA Human genes 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 239000003981 vehicle Substances 0.000 claims description 12
- 208000018737 Parkinson disease Diseases 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 208000010118 dystonia Diseases 0.000 claims description 10
- 208000014094 Dystonic disease Diseases 0.000 claims description 9
- 102000003840 Opioid Receptors Human genes 0.000 claims description 8
- 108090000137 Opioid Receptors Proteins 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 8
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 7
- 229960004046 apomorphine Drugs 0.000 claims description 7
- 208000016285 Movement disease Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 206010019196 Head injury Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010012335 Dependence Diseases 0.000 claims description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 150000002540 isothiocyanates Chemical class 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- 239000011572 manganese Substances 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- AJPSBXJNFJCCBI-YOHUGVJRSA-N naloxonazine Chemical compound C([C@@H](N(CC1)CC=C)[C@]2(O)CC\C3=N/N=C4/[C@H]5[C@]67CCN(CC=C)[C@@H]([C@@]7(CC4)O)CC4=CC=C(C(O5)=C46)O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 AJPSBXJNFJCCBI-YOHUGVJRSA-N 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims 1
- PQKHESYTSKMWFP-WZJCLRDWSA-N beta-Funaltrexamine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3NC(=O)/C=C/C(=O)OC)CN2CC1CC1 PQKHESYTSKMWFP-WZJCLRDWSA-N 0.000 claims 1
- 208000011110 idiopathic torsion dystonia Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 8
- INUCRGMCKDQKNA-CEMLEFRQSA-N cyprodime Chemical compound N1([C@@H]2CC=3C=CC=C(C=3[C@@]3([C@]2(CCC(=O)C3)OC)CC1)OC)CC1CC1 INUCRGMCKDQKNA-CEMLEFRQSA-N 0.000 abstract description 2
- 239000013598 vector Substances 0.000 description 13
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 11
- 229960003086 naltrexone Drugs 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 230000033001 locomotion Effects 0.000 description 10
- DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 description 9
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 8
- 230000005540 biological transmission Effects 0.000 description 7
- 229960003638 dopamine Drugs 0.000 description 6
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 6
- 108020001588 κ-opioid receptors Proteins 0.000 description 6
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- 206010008748 Chorea Diseases 0.000 description 5
- APSUXPSYBJVPPS-YAUKWVCOSA-N Norbinaltorphimine Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 APSUXPSYBJVPPS-YAUKWVCOSA-N 0.000 description 5
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 5
- 208000012601 choreatic disease Diseases 0.000 description 5
- 108700023159 delta Opioid Receptors Proteins 0.000 description 5
- 102000048124 delta Opioid Receptors Human genes 0.000 description 5
- 238000009256 replacement therapy Methods 0.000 description 5
- 241000269799 Perca fluviatilis Species 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 206010006100 Bradykinesia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 208000015592 Involuntary movements Diseases 0.000 description 2
- 101000783705 Myxoma virus (strain Uriarra) Envelope protein A28 homolog Proteins 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000648 anti-parkinson Effects 0.000 description 2
- 239000000939 antiparkinson agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 2
- 230000000142 dyskinetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000002618 kappa opiate receptor antagonist Substances 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002756 mu opiate receptor agonist Substances 0.000 description 2
- 229940126487 mu opioid receptor agonist Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 2
- 239000003401 opiate antagonist Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- QIMGSZURBOTPMW-UHFFFAOYSA-N 2-methoxy-5-(2,3,4-trimethoxyphenyl)cyclohepta-2,4,6-trien-1-one Chemical compound COC1=C(OC)C(OC)=CC=C1C1=CC=C(OC)C(=O)C=C1 QIMGSZURBOTPMW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000009017 Athetosis Diseases 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 241000288950 Callithrix jacchus Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 238000001135 Friedman test Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000005903 Manganese Poisoning Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229940121954 Opioid receptor agonist Drugs 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000003374 anti-dyskinetic effect Effects 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000857 delta opiate receptor antagonist Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000011294 monotherapeutic Methods 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007230 neural mechanism Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 230000009183 running Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000009184 walking Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Resistance Heating (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815618.5A GB9815618D0 (en) | 1998-07-18 | 1998-07-18 | Treatment of dyskinesia |
| GB9815618.5 | 1998-07-18 | ||
| PCT/GB1999/002146 WO2000003715A1 (en) | 1998-07-18 | 1999-07-16 | Treatment of dyskinesia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010228049A Division JP2011037877A (ja) | 1998-07-18 | 2010-10-08 | ジスキネジーの治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002520362A true JP2002520362A (ja) | 2002-07-09 |
| JP2002520362A5 JP2002520362A5 (OSRAM) | 2006-08-03 |
Family
ID=10835727
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000559850A Pending JP2002520362A (ja) | 1998-07-18 | 1999-07-16 | ジスキネジーの治療 |
| JP2010228049A Withdrawn JP2011037877A (ja) | 1998-07-18 | 2010-10-08 | ジスキネジーの治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010228049A Withdrawn JP2011037877A (ja) | 1998-07-18 | 2010-10-08 | ジスキネジーの治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US6455536B1 (OSRAM) |
| EP (2) | EP1096936B1 (OSRAM) |
| JP (2) | JP2002520362A (OSRAM) |
| AT (1) | ATE357917T1 (OSRAM) |
| AU (1) | AU759342B2 (OSRAM) |
| CA (1) | CA2338066C (OSRAM) |
| CY (1) | CY1108054T1 (OSRAM) |
| DE (1) | DE69935670T2 (OSRAM) |
| DK (1) | DK1096936T3 (OSRAM) |
| ES (1) | ES2285845T3 (OSRAM) |
| GB (1) | GB9815618D0 (OSRAM) |
| PT (1) | PT1096936E (OSRAM) |
| WO (1) | WO2000003715A1 (OSRAM) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014523404A (ja) * | 2011-04-29 | 2014-09-11 | ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー | ジスキネジーの治療方法 |
| US9918980B2 (en) | 2011-04-29 | 2018-03-20 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
| US10736889B2 (en) | 2011-04-29 | 2020-08-11 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
| US12274696B2 (en) | 2020-01-10 | 2025-04-15 | Trevi Therapeutics, Inc. | Methods of administering nalbuphine |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815618D0 (en) * | 1998-07-18 | 1998-09-16 | Univ Manchester | Treatment of dyskinesia |
| GB9924941D0 (en) * | 1999-10-22 | 1999-12-22 | Univ Manchester | Treatment of dyskinesia |
| GB0007193D0 (en) * | 2000-03-25 | 2000-05-17 | Univ Manchester | Treatment of movrmrnt disorders |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| GB0027020D0 (en) * | 2000-11-03 | 2000-12-20 | Univ Manchester | Treatment of movement disorders |
| US20060177381A1 (en) * | 2002-02-15 | 2006-08-10 | Howard Brooks-Korn | Opiopathies |
| DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| CA2580694A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| JP2006131545A (ja) * | 2004-11-05 | 2006-05-25 | Japan Science & Technology Agency | 神経因性疼痛治療剤 |
| WO2008133297A1 (ja) | 2007-04-24 | 2008-11-06 | Toray Industries, Inc. | ジスキネジアの治療または予防剤 |
| US8138169B2 (en) | 2008-04-11 | 2012-03-20 | Comgenrx, Inc. | Combination therapy for bipolar disorder |
| US20100168119A1 (en) * | 2008-11-05 | 2010-07-01 | Pharmorx, Inc. | Compositions and methods for minimizing or reducing agonist-induced desensitization |
| JP6406713B2 (ja) | 2013-01-30 | 2018-10-17 | ファーモレックス セラピューティクス， インコーポレイテッド | 低用量薬剤によるうつ病および他の疾患の処置 |
| EP3436013A4 (en) | 2016-03-31 | 2019-11-13 | Versi Group, LLC | DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHOD FOR TREATING MORBUS PARKINSON |
| US12384197B2 (en) | 2022-07-15 | 2025-08-12 | Swimc Llc | Coating material container |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06505747A (ja) * | 1991-02-25 | 1994-06-30 | トラスティーズ・オブ・ボストン・ユニバーシティ | 多動運動障害を変調するアヘン剤受容体アンタゴニスト |
| JPH08512129A (ja) * | 1993-06-23 | 1996-12-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗常習性麻酔鎮痛活性スクリーニングのための組成物および方法並びに治療 |
| JPH09505052A (ja) * | 1993-11-08 | 1997-05-20 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 免疫調節障害の治療 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4390699A (en) | 1981-07-16 | 1983-06-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | 6-Keto-morphinans belonging to the 14-hydroxy-series |
| US4684620A (en) * | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| ATE110057T1 (de) * | 1987-04-16 | 1994-09-15 | Lilly Co Eli | Piperidine als opioid-antagoniste. |
| US5473620A (en) | 1993-09-21 | 1995-12-05 | Cirrus Logic, Inc. | Programmable redundancy/syndrome generator |
| US5597309A (en) * | 1994-03-28 | 1997-01-28 | Riess; Thomas | Method and apparatus for treatment of gait problems associated with parkinson's disease |
| US5496836A (en) * | 1994-05-05 | 1996-03-05 | Mount Sinai School Of Medicine Of The City University Of New York | Use of famotidine and related compounds in the treatment of movement disorders |
| US5821219A (en) * | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
| GB9815618D0 (en) * | 1998-07-18 | 1998-09-16 | Univ Manchester | Treatment of dyskinesia |
-
1998
- 1998-07-18 GB GBGB9815618.5A patent/GB9815618D0/en not_active Ceased
-
1999
- 1999-07-16 JP JP2000559850A patent/JP2002520362A/ja active Pending
- 1999-07-16 EP EP99932991A patent/EP1096936B1/en not_active Expired - Lifetime
- 1999-07-16 DK DK99932991T patent/DK1096936T3/da active
- 1999-07-16 US US09/743,965 patent/US6455536B1/en not_active Expired - Lifetime
- 1999-07-16 AT AT99932991T patent/ATE357917T1/de active
- 1999-07-16 WO PCT/GB1999/002146 patent/WO2000003715A1/en not_active Ceased
- 1999-07-16 EP EP07003196A patent/EP1792617A1/en not_active Withdrawn
- 1999-07-16 ES ES99932991T patent/ES2285845T3/es not_active Expired - Lifetime
- 1999-07-16 PT PT99932991T patent/PT1096936E/pt unknown
- 1999-07-16 AU AU49180/99A patent/AU759342B2/en not_active Ceased
- 1999-07-16 CA CA002338066A patent/CA2338066C/en not_active Expired - Fee Related
- 1999-07-16 DE DE69935670T patent/DE69935670T2/de not_active Expired - Lifetime
-
2002
- 2002-05-20 US US10/147,853 patent/US20020137669A1/en not_active Abandoned
- 2002-08-02 US US10/210,061 patent/US6740659B2/en not_active Expired - Lifetime
-
2004
- 2004-04-07 US US10/819,345 patent/US20050009856A1/en not_active Abandoned
-
2007
- 2007-06-21 CY CY20071100828T patent/CY1108054T1/el unknown
-
2009
- 2009-08-31 US US12/585,014 patent/US8198294B2/en not_active Expired - Fee Related
-
2010
- 2010-10-08 JP JP2010228049A patent/JP2011037877A/ja not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06505747A (ja) * | 1991-02-25 | 1994-06-30 | トラスティーズ・オブ・ボストン・ユニバーシティ | 多動運動障害を変調するアヘン剤受容体アンタゴニスト |
| JPH08512129A (ja) * | 1993-06-23 | 1996-12-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗常習性麻酔鎮痛活性スクリーニングのための組成物および方法並びに治療 |
| JPH09505052A (ja) * | 1993-11-08 | 1997-05-20 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 免疫調節障害の治療 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014523404A (ja) * | 2011-04-29 | 2014-09-11 | ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー | ジスキネジーの治療方法 |
| US9918980B2 (en) | 2011-04-29 | 2018-03-20 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
| US10736889B2 (en) | 2011-04-29 | 2020-08-11 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
| US12274696B2 (en) | 2020-01-10 | 2025-04-15 | Trevi Therapeutics, Inc. | Methods of administering nalbuphine |
Also Published As
| Publication number | Publication date |
|---|---|
| AU4918099A (en) | 2000-02-07 |
| DE69935670T2 (de) | 2008-01-31 |
| CA2338066A1 (en) | 2000-01-27 |
| CA2338066C (en) | 2009-01-27 |
| WO2000003715A1 (en) | 2000-01-27 |
| ATE357917T1 (de) | 2007-04-15 |
| DK1096936T3 (da) | 2007-07-30 |
| DE69935670D1 (de) | 2007-05-10 |
| CY1108054T1 (el) | 2013-09-04 |
| EP1096936B1 (en) | 2007-03-28 |
| EP1792617A1 (en) | 2007-06-06 |
| US8198294B2 (en) | 2012-06-12 |
| GB9815618D0 (en) | 1998-09-16 |
| JP2011037877A (ja) | 2011-02-24 |
| US20100184797A1 (en) | 2010-07-22 |
| US6740659B2 (en) | 2004-05-25 |
| US20020137669A1 (en) | 2002-09-26 |
| EP1096936A1 (en) | 2001-05-09 |
| US20050009856A1 (en) | 2005-01-13 |
| US6455536B1 (en) | 2002-09-24 |
| AU759342B2 (en) | 2003-04-10 |
| US20030060478A1 (en) | 2003-03-27 |
| ES2285845T3 (es) | 2007-11-16 |
| PT1096936E (pt) | 2007-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8198294B2 (en) | Treatment of dyskinesia | |
| AU2001242568B2 (en) | Treatment of movement disorders | |
| AU2001242568A1 (en) | Treatment of movement disorders | |
| JP2002520362A5 (OSRAM) | ||
| JP2007509146A (ja) | レボドーパの持続効果のための組成物及び投与形 | |
| CA2389476C (en) | Treatment of dyskinesia with a h3-histamine receptor agonist | |
| JP2010241827A (ja) | ５−ヒドロキシトリプタミン１ａレセプター活性増強化合物を用いる運動症状の変動の治療 | |
| EP3615023B1 (en) | Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury | |
| EP1545546B1 (en) | Treatment of dyskinesia with 2,3-benzodiazepines | |
| WO2004105756A2 (en) | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof | |
| JP2003503452A (ja) | 治療剤 | |
| US20030073683A1 (en) | Administration of noncompetitive AMPA receptor antagonist for neuroprotection after traumatic brain injury | |
| HK40016595A (en) | Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury | |
| HK40016595B (en) | Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury | |
| JP2014523404A (ja) | ジスキネジーの治療方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060613 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060613 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090818 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091106 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091113 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100218 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100218 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100608 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101008 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20101208 |